Unituxin (dinutuximab)

pCPA File Number: 21540

Negotiation Status:

Concluded with an LOI

Indication(s):

high-risk neuroblastoma patients in their first relapse or determination of refractory disease, in combination with irinotecan, temozolomide, and granulocyte macrophage colony-stimulating factor

Sponsor/Manufacturer:

United Therapeutics

CADTH Project Number:

PC0222

pCPA Engagement Letter Issued:

2021-11-16

Negotiation Process Concluded:

2022-02-24